~~<i id='5B27A07113'><strike id='5B27A07113'><tt id='5B27A07113'><pre id='5B27A07113'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

explore

author：fashion 2025-08-04 03:41:59 - browse：93526

A green number 3 with an eye is surrounded by smaller, black number 3s on a purple background — 3 to watch coverage from STAT — Christine Kao/STAT

Life in the CRISPR lane tends to move at lightning speed. This year saw the first-ever approval of a medicine based on the gene editing technology, barely more than a decade after publication of its first demonstration by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier.

The landmark decision paves the way for in vivo therapies, which edit cells inside the body, to reach patients, as well as treatments based on more efficient genome editors with fancier DNA-altering tricks up their sleeves.

Here are three CRISPR developments we’re watching in 2024:

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

entertainment

leisure time

entertainment

focus

hotspot

focus

SEBASTIENBOZON/AFPviaGettyImagesNovoNordisk’sOzempiccuttheriskofdeathinatrialofpatientswithtype2diab

WSS

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

Vir antibody drug aimed at influenza A fails in clinical trial

Ending racial health disparities hinges on penalties, political will

7 more heat

Asahi Kasei to buy Calliditas, picking up kidney disease drug

Ozempic cut risk of death in diabetes patients with chronic kidney disease

leisure time

explore

entertainment

Trump demands the U.S. pay no more for drugs than other countries … again

Protect nursing home residents from future pandemics

Novavax promises a turnaround & Lilly roils the obesity market

Study identifies new proteins linked to dementia risk 25 years later

Cancer drug shortages should be causing more outrage

Protect nursing home residents from future pandemics

Continuity nursing helped my family in our darkest PICU moments

I learned firsthand about improving diversity in clinical trials

23andMe had bad news about my health. I wish a person had delivered it

Decentralized clinical trials need collaboration to achieve wider use

leisure time

Indian pharmaceutical industry in denial over drug

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

Guardant Health colon cancer test endorsed by FDA advisory panel

New research sheds light on how often breast cancer is overdiagnosed

Beyond aggravation: Constipation is an American epidemic

Tesla recalling nearly 16,000 of its 2021

entertainment

focus

hotspot

focus